<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02836925</url>
  </required_header>
  <id_info>
    <org_study_id>FIL_BArT</org_study_id>
    <nct_id>NCT02836925</nct_id>
  </id_info>
  <brief_title>Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection</brief_title>
  <official_title>A Multicenter Study to Evaluate the Anti-viral Activity of an Interferon-free Treatment With Ledipasvir/Sofosbuvir (G1 and G4) and Sofosbuvir/Velpatasvir (G2 and G3) for Patients With Hepatitis C Virus-associated Indolent B-cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-randomized, a single arm, phase II multicentre study of sofosbuvir plus&#xD;
      ledipasvir (genotype 1 and 4) or sofosbuvir plus velpatasvir (genotype 2 and 3) for patients&#xD;
      with hepatitis C virus-associated indolent B-cell lymphomas (HCV-RNA positive).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study includes an antiviral treatment with interferon-free regimen followed by lymphoma&#xD;
      restaging; following the end of antiviral treatment patients will be evaluated for sustained&#xD;
      virological response and safety parameters every 3 months for 1 year and then every 6 months&#xD;
      for 2 years. ORR and vital status will be also evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Actual">February 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SVR12</measure>
    <time_frame>12 weeks from the end of the treatment</time_frame>
    <description>Sustained virologic response (SVR12) defined as undetectability of HCV-RNA 12 weeks after completion of antiviral therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>12 weeks from the end of treatment</time_frame>
    <description>Overall response rate (ORR) of lymphoma: CR is defined by the complete disappearance of all detectable sites and symptoms; PR is defined as a more than 50% reduction. Responses different from CR/PR are defined as stable disease (SD); progressive disease (PD) is considered an increase in size of more than 50% of previously documented disease or the appearance of new lesions. Lymphoma response will be assessed 12 weeks after the end of antiviral treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>36 months</time_frame>
    <description>Progression-free survival (PFS) defined as the time between enrolment and progression or relapse or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EFS</measure>
    <time_frame>36 months</time_frame>
    <description>Event-free survival (EFS) defined as time between enrolment and failure of treatment or death as a result of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>36 months</time_frame>
    <description>Overall survival (OS) defined as the time between enrolment and death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR for lymphoma</measure>
    <time_frame>12 weeks from the end of treatment</time_frame>
    <description>ORR for lymphoma according to Matutes criteria (Matutes et al, Leukemia 2008) only in patients with splenic-marginal zone lymphoma (SMZL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rapid virological response</measure>
    <time_frame>4 weeks</time_frame>
    <description>rapid virologic response (RVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extended rapid virological response</measure>
    <time_frame>4 weeks</time_frame>
    <description>extended RVR (eRVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early virological response</measure>
    <time_frame>4 weeks</time_frame>
    <description>early virologic response (EVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity - Incidence of Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>toxicity will be classified according to definitions of Common Terminology Criteria for Adverse Event version 4.03 (CTCAE). It will be determined by the incidence of severe, life-threatening (CTCAE grade 3, 4 and 5) and/or serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Indolent B-cell Lymphoma</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Ledipasvir+Sofosbuvir,Sofosbuvir+Velpatasvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study includes an antiviral treatment with interferon-free regimen followed by lymphoma restaging; following the end of antiviral treatment patients will be evaluated for sustained virological response and safety parameters every 3 months for 1 year and then every 6 months for 2 years. ORR and vital status will be also evaluated</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ledipasvir+Sofosbuvir</intervention_name>
    <description>Patients with genotype 1 or genotype 4 Ledipasvir 90 mg + Sofosbuvir 400 mg&#xD;
12 weeks in previously untreated infected patients&#xD;
24 weeks for previously treated patients with uncertain subsequent retreatment options</description>
    <arm_group_label>Ledipasvir+Sofosbuvir,Sofosbuvir+Velpatasvir</arm_group_label>
    <other_name>Harvoni</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir+Velpatasvir</intervention_name>
    <description>Patients with genotype 2 or genotype 3 Sofosbuvir 400 mg + Velpatasvir 100 mg&#xD;
· 12 weeks of treatment</description>
    <arm_group_label>Ledipasvir+Sofosbuvir,Sofosbuvir+Velpatasvir</arm_group_label>
    <other_name>Epclusa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;18 years&#xD;
&#xD;
          2. Indolent B cell lymphoma including: marginal zone lymphoma (nodal, extranodal, splenic&#xD;
             and disseminated), lymphoplasmacytic lymphoma, small lymphocytic lymphoma, follicular&#xD;
             lymphoma grade 1 and 2, CD5-negative B-cell lymphoma NOS&#xD;
&#xD;
          3. HCV-RNA positivity&#xD;
&#xD;
          4. Assessable HCV genotype&#xD;
&#xD;
          5. No previous therapy for the lymphoma&#xD;
&#xD;
          6. Measurable disease after diagnostic biopsy (longest axis ≥1.5 cm for nodal and ≥1 cm&#xD;
             for extranodal lesions) and/or evaluable disease (quantifiable BM infiltrate and ≥5 x&#xD;
             109/l clonal B-cell in peripheral blood in case of exclusive BM/leukemic disease in&#xD;
             CD5-negative Bcell lymphoma NOS)&#xD;
&#xD;
          7. No need of immediate lymphoma treatment defined as absence of all the following&#xD;
             criteria: systemic symptoms, bulky nodal or extranodal mass (&gt;7 cm), symptomatic&#xD;
             splenomegaly, progressive leukemic phase, serous effusions&#xD;
&#xD;
          8. Performance status &lt;2 according to ECOG scale&#xD;
&#xD;
          9. Adequate hematological counts: ANC &gt;1 x 109/L, hemoglobin &gt;9 g/dl (transfusion&#xD;
             independent), platelet count &gt; 50 x 109/L (transfusion independent)&#xD;
&#xD;
         10. No central nervous system (CNS) disease (meningeal and/or brain involvement by&#xD;
             lymphoma)&#xD;
&#xD;
         11. Adequate kidney function (creatinine clearance ≥ 45 ml/min)&#xD;
&#xD;
         12. Cardiac ejection fraction ≥45% (echocardiography or MUGA scan)&#xD;
&#xD;
         13. Normal lung function&#xD;
&#xD;
         14. Non peripheral neuropathy or active neurological non neoplastic disease of CNS&#xD;
&#xD;
         15. Non major surgical intervention prior 3 months to enrolment if not due to lymphoma&#xD;
             and/or no other disease life-threatening that can compromise chemotherapy treatment&#xD;
&#xD;
         16. Disease free of prior malignancies other than lymphoma for &gt;3 years with exception of&#xD;
             currently treated squamous cell and basal cell carcinoma of the skin or carcinoma in&#xD;
             situ of the cervix or breast&#xD;
&#xD;
         17. Life expectancy &gt; 6 months&#xD;
&#xD;
         18. No psychiatric illness that precludes understanding concepts of the trial or signing&#xD;
             informed consent&#xD;
&#xD;
         19. Written informed consent&#xD;
&#xD;
         20. Women must be:&#xD;
&#xD;
               -  postmenopausal for at least 1 year (must not have had a natural menses for at&#xD;
                  least 12 months)&#xD;
&#xD;
               -  surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal&#xD;
                  ligation, or otherwise be incapable of pregnancy),&#xD;
&#xD;
               -  completely abstinent (at the discretion of the investigator/per local&#xD;
                  regulations) (periodic abstinence from intercourse is not permitted) or&#xD;
&#xD;
               -  if sexually active, be practicing a highly effective method of birth control (eg,&#xD;
                  prescription oral contraceptives, contraceptive injections, contraceptive patch,&#xD;
                  intrauterine device, double-barrier method (eg: condoms, diaphragm, or cervical&#xD;
                  cap, with spermicidal foam, cream, or gel, male partner sterilization) as local&#xD;
                  regulations permit, before entry, and must agree to continue to use the same&#xD;
                  method of contraception throughout the study. They must also be prepared to&#xD;
                  continue birth control measures for at least 6 months after terminating&#xD;
                  treatment.&#xD;
&#xD;
         21. Women of childbearing potential must have a negative serum or urine beta-human&#xD;
             chorionic gonadotropin (beta-hCG) pregnancy test at screening&#xD;
&#xD;
         22. Men must agree to use an acceptable method of contraception (for themselves or female&#xD;
             partners as listed above) for the duration of the study. Men must agree to use a&#xD;
             double barrier method of birth control and to not donate sperm during the study and&#xD;
             for 1 month after receiving the last dose of study drug if not taking ribavirin of for&#xD;
             6 months after receiving the last dose of study drug if taking ribavirin.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of lymphoblastic lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma,&#xD;
             mantle cell lymphoma, follicular lymphoma grade 3, primary mediastinal B-cell lymphoma&#xD;
&#xD;
          2. Previous anti-HCV treatment with sustained virological response&#xD;
&#xD;
          3. Diagnosis of cirrhosis (histological or Stiffness &gt;12 KpA)&#xD;
&#xD;
          4. CNS disease (meningeal and/or brain involvement by lymphoma)&#xD;
&#xD;
          5. History of clinically relevant liver or renal insufficiency; significant cardiac,&#xD;
             vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic,&#xD;
             hematologic, psychiatric, or metabolic disturbances&#xD;
&#xD;
          6. Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable&#xD;
             dose for at least 3 months before first dose of study drug)&#xD;
&#xD;
          7. Concomitant therapy with amiodarone&#xD;
&#xD;
          8. Uncontrolled or severe cardiovascular disease including myocardial infarction within&#xD;
             six months of enrollment, New York Heart Association (NYHA) Class III or IV heart&#xD;
             failure, uncontrolled angina,&#xD;
&#xD;
          9. Cardiac ejection fraction &lt;45% (MUGA scan or echocardiography).&#xD;
&#xD;
         10. Creatinine clearance &lt;45 ml/min&#xD;
&#xD;
         11. Presence of major neurological disorders&#xD;
&#xD;
         12. HIV positivity, HBV positivity (HbsAg+ or HBV-DNA+) with the exception of HBcAb+,&#xD;
             HbsAg-, HBsAb+/- patients with HBV-DNA negativity&#xD;
&#xD;
         13. Ongoing systemic bacterial, fungal or viral infections at the time of initiation of&#xD;
             study treatment (defined as requiring therapeutic dosing of an antimicrobial,&#xD;
             antifungal or antiviral agent)&#xD;
&#xD;
         14. Major surgical intervention prior 3 months to enrollment if not due to lymphoma and/or&#xD;
             other&#xD;
&#xD;
         15. Prior malignancies other than lymphoma in the last 3 years with exception of currently&#xD;
             treated squamous cell and basal cell carcinoma of the skin or carcinoma in situ of the&#xD;
             cervix or breast&#xD;
&#xD;
         16. Life expectancy &lt;6 months&#xD;
&#xD;
         17. Any other coexisting medical or psychological condition that would preclude&#xD;
             participation in the study or compromise ability to give informed consent.&#xD;
&#xD;
         18. If female, the patient is pregnant or breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Arcaini</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Policlinico San Matteo di Pavia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>A.O. Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Centro Di Riferimento Oncologico (Cro)</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <zip>33801</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Bortolo</name>
      <address>
        <city>Vicenza</city>
        <state>VI</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia e Trapianto IRCCS, Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele Ematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia AO di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Piacenza</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia - Policlinico Umberto I Università Sapienza</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia Medica ed Ematologia, Istituto Humanitas</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo e Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 25, 2016</study_first_submitted>
  <study_first_submitted_qc>July 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2016</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatitis C</keyword>
  <keyword>NHL</keyword>
  <keyword>Indolent B-cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
    <mesh_term>Velpatasvir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

